newsfilter
← Latest News
PR Newswire·

Q32 Bio to Participate in the 2026 Jefferies Global Healthcare Conference in London

  • Q32 Bio Inc. (Nasdaq: QTTB) announced management will participate in a fireside chat at 12 p.m. GMT (7 a.m. ET) on Wednesday, November 18, 2026.
  • The event will take place at the 2026 Jefferies Global Healthcare Conference in London.
  • A webcast of the presentation will be available on the Events & Presentations page of the company's website, with an archived replay accessible for 90 days post-event.
  • Q32 Bio is a clinical-stage biotechnology company developing therapies for alopecia areata (AA) & other autoimmune & inflammatory diseases.
  • The company is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody, in an ongoing Phase 2 program for AA treatment.
  • Approximately 700,000 people in the United States live with alopecia areata, a condition with limited current treatment options.
  • The IL-7 & TSLP pathways are implicated in driving T cell-mediated pathological processes in various autoimmune diseases.
  • Investor & public information is disseminated via the company website, SEC filings, press releases, conference calls, X, & LinkedIn.
Company
Q32 Bio
Keywords
Q32 Bio